GlassScriptPhysician profile
Chad A Wadell
NPI 1144436262
$3,653.02
in general payments reported to CMS, 2019-2025
33 companies · $786 in 2025
The $786 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $164 · 2021: $363 · 2022: $261 · 2023: $597 · 2024: $753 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,135.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $616.93 | 2022-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $352.53 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $285.43 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $224.35 | 2019-2024 | Airsupra |
| Pfizer INC. | $215.25 | 2019-2021 | |
| Astellas Pharma US INC | $195.10 | 2019-2025 | Veozah |
| Amgen INC. | $184.64 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $155.48 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| New World Medical,INC. | $147.43 | 2025 | Streamline, Clearpath, Via360 |
| Edwards Lifesciences Corporation | $146.63 | 2021 | |
| Intuitive Surgical, INC. | $126.11 | 2025 | |
| Inari Medical, INC. | $122.74 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lilly USA, LLC | $104.33 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Janssen Pharmaceuticals, INC | $102.50 | 2019-2024 | Xarelto |
| Abbvie INC. | $72.23 | 2021-2023 | Creon, Linzess |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $71.58 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $58.78 | 2019-2024 | |
| Allergan, INC. | $56.88 | 2019-2020 | |
| Exact Sciences Corporation | $54.73 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $41.74 | 2019-2022 | |
| Ibsa Pharma INC. | $39.42 | 2025 | Licart, Flector, Tirosint |
| Verity Pharmaceuticals INC. | $38.41 | 2024 | Tlando |
| Merck Sharp & Dohme LLC | $35.81 | 2019 | |
| Boston Scientific Corporation | $29.38 | 2019-2022 | |
| Almatica Pharma LLC | $26.80 | 2023 | Loreev Xr |
| Gilead Sciences, INC. | $25.12 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.32 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $20.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.56 | 2019 | |
| Antares Pharma, INC. | $18.52 | 2019 | |
| Sumitomo Pharma America, INC. | $16.75 | 2024 | Gemtesa |
| Therapeuticsmd, INC. | $13.26 | 2019 | |
| Endogastric Solutions, INC | $9.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Wadell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.